Specifically, in recent years, type I K17 was identified as present in the nucleus and involved in altering the nuclear localization and function of 14-3-3δ, the cell cycle inhibitor p27KIP1, and the heterogeneous ribonucleoprotein hnRNP K, suggesting a possible role for K17 in protein synthesis, proliferation of carcinoma cells, and inflammatory gene expression (32–34). Here, CDKN1B is linked to carcinoma.